{
  "DOI": "10.1186/s40246-018-0157-3",
  "ISSN": [
    "1479-7364"
  ],
  "URL": "http://dx.doi.org/10.1186/s40246-018-0157-3",
  "alternative-id": [
    "157"
  ],
  "article-number": "26",
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "6 March 2018"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "8 May 2018"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "25 May 2018"
    },
    {
      "group": {
        "label": "Ethics approval and consent to participate",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "In this study, only publically available, anonymized data released under the Fort Lauderdale Agreement was analyzed, and thus, separate ethical approval was not required."
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare that they have no competing interests."
    },
    {
      "group": {
        "label": "Publisher’s Note",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Ingelman-Sundberg",
      "given": "Magnus",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Mkrtchian",
      "given": "Souren",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Zhou",
      "given": "Yitian",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-1140-6204",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Lauschke",
      "given": "Volker M.",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genomics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2018,
        5,
        21
      ]
    ],
    "date-time": "2018-05-21T08:02:12Z",
    "timestamp": 1526889732000
  },
  "deposited": {
    "date-parts": [
      [
        2019,
        5,
        24
      ]
    ],
    "date-time": "2019-05-24T19:08:27Z",
    "timestamp": 1558724907000
  },
  "funder": [
    {
      "DOI": "10.13039/501100004359",
      "award": [
        "2015-02760",
        "2016-01153",
        "2016-01154"
      ],
      "doi-asserted-by": "publisher",
      "name": "Vetenskapsrådet"
    },
    {
      "DOI": "10.13039/100010663",
      "award": [
        "668353"
      ],
      "doi-asserted-by": "publisher",
      "name": "H2020 European Research Council"
    },
    {
      "award": [
        "2017"
      ],
      "name": "Lennart Philipson Foundation"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        27
      ]
    ],
    "date-time": "2024-04-27T07:02:27Z",
    "timestamp": 1714201347668
  },
  "is-referenced-by-count": 158,
  "issn-type": [
    {
      "type": "electronic",
      "value": "1479-7364"
    }
  ],
  "issue": "1",
  "issued": {
    "date-parts": [
      [
        2018,
        5,
        25
      ]
    ]
  },
  "journal-issue": {
    "issue": "1",
    "published-print": {
      "date-parts": [
        [
          2018,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "http://creativecommons.org/licenses/by/4.0/",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2018,
            5,
            25
          ]
        ],
        "date-time": "2018-05-25T00:00:00Z",
        "timestamp": 1527206400000
      }
    }
  ],
  "link": [
    {
      "URL": "http://link.springer.com/content/pdf/10.1186/s40246-018-0157-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/article/10.1186/s40246-018-0157-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1186/s40246-018-0157-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "prefix": "10.1186",
  "published": {
    "date-parts": [
      [
        2018,
        5,
        25
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2018,
        5,
        25
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2018,
        12
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.3390/ijms17101714",
      "author": "VM Lauschke",
      "doi-asserted-by": "publisher",
      "first-page": "1714",
      "issue": "10",
      "journal-title": "Int J Mol Sci",
      "key": "157_CR1",
      "unstructured": "Lauschke VM, Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016;17(10):1714–27. \n                    https://doi.org/10.3390/ijms17101714\n                    \n                  .",
      "volume": "17",
      "year": "2016"
    },
    {
      "DOI": "10.1136/bmj.329.7456.15",
      "author": "M Pirmohamed",
      "doi-asserted-by": "publisher",
      "first-page": "15",
      "issue": "7456",
      "journal-title": "BMJ",
      "key": "157_CR2",
      "unstructured": "Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9. \n                    https://doi.org/10.1136/bmj.329.7456.15\n                    \n                  .",
      "volume": "329",
      "year": "2004"
    },
    {
      "DOI": "10.1038/tpj.2012.45",
      "author": "SC Sim",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "issue": "1",
      "journal-title": "Pharmacogenomics J",
      "key": "157_CR3",
      "unstructured": "Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2012;13(1):1–11. \n                    https://doi.org/10.1038/tpj.2012.45\n                    \n                  .",
      "volume": "13",
      "year": "2012"
    },
    {
      "DOI": "10.1002/cpt.258",
      "author": "J Matthaei",
      "doi-asserted-by": "publisher",
      "first-page": "611",
      "issue": "6",
      "journal-title": "Clin Pharmacol Ther",
      "key": "157_CR4",
      "unstructured": "Matthaei J, Brockmöller J, Tzvetkov MV, et al. Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther. 2015;98(6):611–21. \n                    https://doi.org/10.1002/cpt.258\n                    \n                  .",
      "volume": "98",
      "year": "2015"
    },
    {
      "DOI": "10.1208/s12248-017-0161-x",
      "author": "VM Lauschke",
      "doi-asserted-by": "publisher",
      "first-page": "4",
      "issue": "1",
      "journal-title": "AAPS J",
      "key": "157_CR5",
      "unstructured": "Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy-recent progress and future developments. AAPS J. 2017;20(1):4. \n                    https://doi.org/10.1208/s12248-017-0161-x\n                    \n                  .",
      "volume": "20",
      "year": "2017"
    },
    {
      "DOI": "10.1080/23808993.2015.1120401",
      "author": "RR Singh",
      "doi-asserted-by": "publisher",
      "first-page": "109",
      "issue": "1",
      "journal-title": "Exp Rev Precision Med Drug Dev",
      "key": "157_CR6",
      "unstructured": "Singh RR, Luthra R, Routbort MJ, et al. Implementation of next generation sequencing in clinical molecular diagnostic laboratories: advantages, challenges and potential. Exp Rev Precision Med Drug Dev. 2016;1(1):109–20. \n                    https://doi.org/10.1080/23808993.2015.1120401\n                    \n                  .",
      "volume": "1",
      "year": "2016"
    },
    {
      "DOI": "10.1093/hmg/ddt588",
      "author": "AS Gordon",
      "doi-asserted-by": "publisher",
      "first-page": "1957",
      "issue": "8",
      "journal-title": "Hum Mol Genet",
      "key": "157_CR7",
      "unstructured": "Gordon AS, Tabor HK, Johnson AD, et al. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. Hum Mol Genet. 2014;23(8):1957–63. \n                    https://doi.org/10.1093/hmg/ddt588\n                    \n                  .",
      "volume": "23",
      "year": "2014"
    },
    {
      "DOI": "10.1097/FPC.0000000000000172",
      "author": "K Fujikura",
      "doi-asserted-by": "publisher",
      "first-page": "584",
      "issue": "12",
      "journal-title": "Pharmacogenet Genomics",
      "key": "157_CR8",
      "unstructured": "Fujikura K, Ingelman-Sundberg M, Lauschke VM. Genetic variation in the human cytochrome P450 supergene family. Pharmacogenet Genomics. 2015;25(12):584–94. \n                    https://doi.org/10.1097/FPC.0000000000000172\n                    \n                  .",
      "volume": "25",
      "year": "2015"
    },
    {
      "DOI": "10.1038/gim.2016.33",
      "author": "M Kozyra",
      "doi-asserted-by": "publisher",
      "first-page": "20",
      "issue": "1",
      "journal-title": "Genet Med",
      "key": "157_CR9",
      "unstructured": "Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20–9. \n                    https://doi.org/10.1038/gim.2016.33\n                    \n                  .",
      "volume": "19",
      "year": "2017"
    },
    {
      "DOI": "10.1002/cpt.350",
      "author": "WS Bush",
      "doi-asserted-by": "publisher",
      "first-page": "160",
      "issue": "2",
      "journal-title": "Clin Pharmacol Ther",
      "key": "157_CR10",
      "unstructured": "Bush WS, Crosslin DR, Owusu-Obeng A, et al. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network. Clin Pharmacol Ther. 2016;100(2):160–9. \n                    https://doi.org/10.1002/cpt.350\n                    \n                  .",
      "volume": "100",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nature19057",
      "author": "M Lek",
      "doi-asserted-by": "publisher",
      "first-page": "285",
      "issue": "7616",
      "journal-title": "Nature",
      "key": "157_CR11",
      "unstructured": "Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–91. \n                    https://doi.org/10.1038/nature19057\n                    \n                  .",
      "volume": "536",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nature15393",
      "author": "GR Abecasis",
      "doi-asserted-by": "publisher",
      "first-page": "68",
      "issue": "7571",
      "journal-title": "Nature",
      "key": "157_CR12",
      "unstructured": "Abecasis GR, Chakravarti A, Donnelly P, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. \n                    https://doi.org/10.1038/nature15393\n                    \n                  .",
      "volume": "526",
      "year": "2015"
    },
    {
      "key": "157_CR13",
      "unstructured": "Zhou Y, Mkrtchian S, Kumondai M, et al. An optimized prediction framework to assess the functional impact of pharmacogenetic variants. Pharmacogenomics J. (In review)"
    },
    {
      "DOI": "10.1126/science.1217876",
      "author": "MR Nelson",
      "doi-asserted-by": "publisher",
      "first-page": "100",
      "issue": "6090",
      "journal-title": "Science",
      "key": "157_CR14",
      "unstructured": "Nelson MR, Wegmann D, Ehm MG, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science. 2012;337(6090):100–4. \n                    https://doi.org/10.1126/science.1217876\n                    \n                  .",
      "volume": "337",
      "year": "2012"
    },
    {
      "DOI": "10.1126/science.1219240",
      "author": "JA Tennessen",
      "doi-asserted-by": "publisher",
      "first-page": "64",
      "issue": "6090",
      "journal-title": "Science",
      "key": "157_CR15",
      "unstructured": "Tennessen JA, Bigham AW, O’Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337(6090):64–9. \n                    https://doi.org/10.1126/science.1219240\n                    \n                  .",
      "volume": "337",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.tcm.2014.09.001",
      "author": "JA Johnson",
      "doi-asserted-by": "publisher",
      "first-page": "33",
      "issue": "1",
      "journal-title": "Trends Cardiovasc Med",
      "key": "157_CR16",
      "unstructured": "Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41. \n                    https://doi.org/10.1016/j.tcm.2014.09.001\n                    \n                  .",
      "volume": "25",
      "year": "2015"
    },
    {
      "DOI": "10.1016/S0163-7258(96)00140-4",
      "author": "LS Kaminsky",
      "doi-asserted-by": "publisher",
      "first-page": "67",
      "issue": "1",
      "journal-title": "Pharmacol Ther",
      "key": "157_CR17",
      "unstructured": "Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73(1):67–74. \n                    https://doi.org/10.1016/s0163-7258(96)00140-4\n                    \n                  .",
      "volume": "73",
      "year": "1997"
    },
    {
      "DOI": "10.1038/sj.tpj.6500220",
      "author": "M Wadelius",
      "doi-asserted-by": "publisher",
      "first-page": "40",
      "issue": "1",
      "journal-title": "Pharmacogenomics J",
      "key": "157_CR18",
      "unstructured": "Wadelius M, Sörlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 2003;4(1):40–8. \n                    https://doi.org/10.1038/sj.tpj.6500220\n                    \n                  .",
      "volume": "4",
      "year": "2003"
    },
    {
      "DOI": "10.1038/clpt.2009.178",
      "author": "E Pautas",
      "doi-asserted-by": "publisher",
      "first-page": "57",
      "issue": "1",
      "journal-title": "Clin Pharmacol Ther",
      "key": "157_CR19",
      "unstructured": "Pautas E, Moreau C, Gouin-Thibault I, et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther. 2009;87(1):57–64. \n                    https://doi.org/10.1038/clpt.2009.178\n                    \n                  .",
      "volume": "87",
      "year": "2009"
    },
    {
      "DOI": "10.1056/NEJMoa0809329",
      "author": "TE Klein",
      "doi-asserted-by": "publisher",
      "first-page": "753",
      "issue": "8",
      "journal-title": "N Engl J Med",
      "key": "157_CR20",
      "unstructured": "The International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753–64. \n                    https://doi.org/10.1056/NEJMoa0809329\n                    \n                  .",
      "volume": "360",
      "year": "2009"
    },
    {
      "DOI": "10.1097/FPC.0b013e3283385a1c",
      "author": "LM Hodges",
      "doi-asserted-by": "publisher",
      "first-page": "152",
      "issue": "3",
      "journal-title": "Pharmacogenet Genomics",
      "key": "157_CR21",
      "unstructured": "Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152–61. \n                    https://doi.org/10.1097/FPC.0b013e3283385a1c\n                    \n                  .",
      "volume": "21",
      "year": "2011"
    },
    {
      "DOI": "10.1056/NEJMoa0801936",
      "author": "E Link",
      "doi-asserted-by": "publisher",
      "first-page": "789",
      "issue": "8",
      "journal-title": "N Engl J Med",
      "key": "157_CR22",
      "unstructured": "SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789–99. \n                    https://doi.org/10.1056/NEJMoa0801936\n                    \n                  .",
      "volume": "359",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.lfs.2008.02.019",
      "author": "M Kobayashi",
      "doi-asserted-by": "publisher",
      "first-page": "969",
      "issue": "17–18",
      "journal-title": "Life Sci",
      "key": "157_CR23",
      "unstructured": "Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci. 2008;82(17–18):969–75. \n                    https://doi.org/10.1016/j.lfs.2008.02.019\n                    \n                  .",
      "volume": "82",
      "year": "2008"
    },
    {
      "DOI": "10.1124/dmd.31.5.540",
      "author": "R Hyland",
      "doi-asserted-by": "publisher",
      "first-page": "540",
      "issue": "5",
      "journal-title": "Drug Metab Dispos",
      "key": "157_CR24",
      "unstructured": "Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–7.",
      "volume": "31",
      "year": "2003"
    },
    {
      "DOI": "10.1124/dmd.107.019646",
      "author": "SB Yanni",
      "doi-asserted-by": "publisher",
      "first-page": "1119",
      "issue": "6",
      "journal-title": "Drug Metab Dispos",
      "key": "157_CR25",
      "unstructured": "Yanni SB, Annaert PP, Augustijns P, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos. 2008;36(6):1119–25. \n                    https://doi.org/10.1124/dmd.107.019646\n                    \n                  .",
      "volume": "36",
      "year": "2008"
    },
    {
      "DOI": "10.1002/phar.1400",
      "author": "A Owusu Obeng",
      "doi-asserted-by": "publisher",
      "first-page": "703",
      "issue": "7",
      "journal-title": "Pharmacotherapy",
      "key": "157_CR26",
      "unstructured": "Owusu Obeng A, Egelund EF, Alsultan A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014;34(7):703–18. \n                    https://doi.org/10.1002/phar.1400\n                    \n                  .",
      "volume": "34",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.xphs.2016.01.007",
      "author": "T Niwa",
      "doi-asserted-by": "publisher",
      "first-page": "1345",
      "issue": "3",
      "journal-title": "J Pharm Sci",
      "key": "157_CR27",
      "unstructured": "Niwa T, Hata T. The effect of genetic polymorphism on the inhibition of azole antifungal agents against CYP2C9-mediated metabolism. J Pharm Sci. 2016;105(3):1345–8. \n                    https://doi.org/10.1016/j.xphs.2016.01.007\n                    \n                  .",
      "volume": "105",
      "year": "2016"
    },
    {
      "DOI": "10.1007/s10096-014-2294-5",
      "author": "HR He",
      "doi-asserted-by": "publisher",
      "first-page": "811",
      "issue": "4",
      "journal-title": "Eur J Clin Microbiol Infect Dis",
      "key": "157_CR28",
      "unstructured": "He HR, Sun JY, Ren XD, et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. Eur J Clin Microbiol Infect Dis. 2014;34(4):811–9. \n                    https://doi.org/10.1007/s10096-014-2294-5\n                    \n                  .",
      "volume": "34",
      "year": "2014"
    },
    {
      "DOI": "10.1097/JCP.0b013e318221b408",
      "author": "MX Patel",
      "doi-asserted-by": "publisher",
      "first-page": "411",
      "issue": "4",
      "journal-title": "J Clin Psychopharmacol",
      "key": "157_CR29",
      "unstructured": "Patel MX, Bowskill S, Couchman L, et al. Plasma olanzapine in relation to prescribed dose and other factors. J Clin Psychopharmacol. 2011;31(4):411–7. \n                    https://doi.org/10.1097/JCP.0b013e318221b408\n                    \n                  .",
      "volume": "31",
      "year": "2011"
    },
    {
      "DOI": "10.1097/00004714-200102000-00004",
      "author": "PJ Perry",
      "doi-asserted-by": "publisher",
      "first-page": "14",
      "issue": "1",
      "journal-title": "J Clin Psychopharmacol",
      "key": "157_CR30",
      "unstructured": "Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21(1):14–20.",
      "volume": "21",
      "year": "2001"
    },
    {
      "DOI": "10.1097/01.jcp.0000162800.64378.82",
      "author": "PJ Perry",
      "doi-asserted-by": "publisher",
      "first-page": "250",
      "issue": "3",
      "journal-title": "J Clin Psychopharmacol",
      "key": "157_CR31",
      "unstructured": "Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25(3):250–4. \n                    https://doi.org/10.1097/01.jcp.0000162800.64378.82\n                    \n                  .",
      "volume": "25",
      "year": "2005"
    },
    {
      "DOI": "10.1097/JCP.0b013e31817e63a5",
      "author": "BJ Kinon",
      "doi-asserted-by": "publisher",
      "first-page": "392",
      "issue": "4",
      "journal-title": "J Clin Psychopharmacol",
      "key": "157_CR32",
      "unstructured": "Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2008;28(4):392–400. \n                    https://doi.org/10.1097/JCP.0b013e31817e63a5\n                    \n                  .",
      "volume": "28",
      "year": "2008"
    },
    {
      "DOI": "10.2217/pgs.13.120",
      "author": "MM Söderberg",
      "doi-asserted-by": "publisher",
      "first-page": "1319",
      "issue": "11",
      "journal-title": "Pharmacogenomics",
      "key": "157_CR33",
      "unstructured": "Söderberg MM, Dahl M-L. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013;14(11):1319–36. \n                    https://doi.org/10.2217/pgs.13.120\n                    \n                  .",
      "volume": "14",
      "year": "2013"
    },
    {
      "DOI": "10.1200/JCO.2003.08.058",
      "author": "CS Fuchs",
      "doi-asserted-by": "publisher",
      "first-page": "807",
      "issue": "5",
      "journal-title": "J Clin Oncol",
      "key": "157_CR34",
      "unstructured": "Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol. 2003;21(5):807–14. \n                    https://doi.org/10.1200/JCO.2003.08.058\n                    \n                  .",
      "volume": "21",
      "year": "2003"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-05-0750",
      "author": "G Brandi",
      "doi-asserted-by": "publisher",
      "first-page": "1299",
      "issue": "4",
      "journal-title": "Clin Cancer Res",
      "key": "157_CR35",
      "unstructured": "Brandi G, Dabard J, Raibaud P, et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res. 2006;12(4):1299–307. \n                    https://doi.org/10.1158/1078-0432.CCR-05-0750\n                    \n                  .",
      "volume": "12",
      "year": "2006"
    },
    {
      "DOI": "10.1038/tpj.2016.58",
      "author": "JM Campbell",
      "doi-asserted-by": "publisher",
      "first-page": "21",
      "issue": "1",
      "journal-title": "Pharmacogenomics J",
      "key": "157_CR36",
      "unstructured": "Campbell JM, Stephenson MD, Bateman E, et al. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics J. 2017;17(1):21–8. \n                    https://doi.org/10.1038/tpj.2016.58\n                    \n                  .",
      "volume": "17",
      "year": "2017"
    },
    {
      "DOI": "10.1002/cncr.22760",
      "author": "J-Y Han",
      "doi-asserted-by": "publisher",
      "first-page": "138",
      "issue": "1",
      "journal-title": "Cancer",
      "key": "157_CR37",
      "unstructured": "Han J-Y, Lim H-S, Yoo Y-K, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007;110(1):138–47. \n                    https://doi.org/10.1002/cncr.22760\n                    \n                  .",
      "volume": "110",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.lungcan.2007.12.003",
      "author": "J-Y Han",
      "doi-asserted-by": "publisher",
      "first-page": "115",
      "issue": "1",
      "journal-title": "Lung Cancer",
      "key": "157_CR38",
      "unstructured": "Han J-Y, Lim H-S, Park YH, et al. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer. 2009;63(1):115–20. \n                    https://doi.org/10.1016/j.lungcan.2007.12.003\n                    \n                  .",
      "volume": "63",
      "year": "2009"
    },
    {
      "DOI": "10.1200/JCO.2008.20.6300",
      "author": "F Innocenti",
      "doi-asserted-by": "publisher",
      "first-page": "2604",
      "issue": "16",
      "journal-title": "J Clin Oncol",
      "key": "157_CR39",
      "unstructured": "Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009;27(16):2604–14. \n                    https://doi.org/10.1200/JCO.2008.20.6300\n                    \n                  .",
      "volume": "27",
      "year": "2009"
    },
    {
      "DOI": "10.1038/tpj.2016.75",
      "author": "M Li",
      "doi-asserted-by": "publisher",
      "first-page": "35",
      "issue": "1",
      "journal-title": "Pharmacogenomics J",
      "key": "157_CR40",
      "unstructured": "Li M, Seiser EL, Baldwin RM, et al. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018;18(1):35–42. \n                    https://doi.org/10.1038/tpj.2016.75\n                    \n                  .",
      "volume": "18",
      "year": "2018"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-09-1526",
      "author": "JM van der Bol",
      "doi-asserted-by": "publisher",
      "first-page": "736",
      "issue": "2",
      "journal-title": "Clin Cancer Res",
      "key": "157_CR41",
      "unstructured": "van der Bol JM, Mathijssen RHJ, Creemers GJM, et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res. 2010;16(2):736–42. \n                    https://doi.org/10.1158/1078-0432.CCR-09-1526\n                    \n                  .",
      "volume": "16",
      "year": "2010"
    },
    {
      "key": "157_CR42",
      "unstructured": "https://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm\n                    \n                  . Accessed 20 May 2017."
    },
    {
      "DOI": "10.1038/tpj.2014.86",
      "author": "F Ehmann",
      "doi-asserted-by": "publisher",
      "first-page": "201",
      "issue": "3",
      "journal-title": "Pharmacogenomics J",
      "key": "157_CR43",
      "unstructured": "Ehmann F, Caneva L, Prasad K, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15(3):201–10. \n                    https://doi.org/10.1038/tpj.2014.86\n                    \n                  .",
      "volume": "15",
      "year": "2015"
    },
    {
      "DOI": "10.1038/gim.2017.156",
      "doi-asserted-by": "publisher",
      "key": "157_CR44",
      "unstructured": "Santos M, Niemi M, Hiratsuka M, et al. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Genet Med. 2017; \n                    https://doi.org/10.1038/gim.2017.156\n                    \n                  . [Epub ahead of print]"
    },
    {
      "DOI": "10.1126/science.1222794",
      "author": "MT Maurano",
      "doi-asserted-by": "publisher",
      "first-page": "1190",
      "issue": "6099",
      "journal-title": "Science",
      "key": "157_CR45",
      "unstructured": "Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337(6099):1190–5. \n                    https://doi.org/10.1126/science.1222794\n                    \n                  .",
      "volume": "337",
      "year": "2012"
    },
    {
      "DOI": "10.1038/ng.3331",
      "author": "D Lee",
      "doi-asserted-by": "publisher",
      "first-page": "955",
      "issue": "8",
      "journal-title": "Nat Genet",
      "key": "157_CR46",
      "unstructured": "Lee D, Gorkin DU, Baker M, et al. A method to predict the impact of regulatory variants from DNA sequence. Nat Genet. 2015;47(8):955–61. \n                    https://doi.org/10.1038/ng.3331\n                    \n                  .",
      "volume": "47",
      "year": "2015"
    },
    {
      "DOI": "10.1111/j.1476-5381.2010.00673.x",
      "author": "CF Samer",
      "doi-asserted-by": "publisher",
      "first-page": "907",
      "issue": "4",
      "journal-title": "Br J Pharmacol",
      "key": "157_CR47",
      "unstructured": "Samer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010;160(4):907–18. \n                    https://doi.org/10.1111/j.1476-5381.2010.00673.x\n                    \n                  .",
      "volume": "160",
      "year": "2010"
    },
    {
      "DOI": "10.1002/cpt.976",
      "author": "VM Lauschke",
      "doi-asserted-by": "publisher",
      "first-page": "20",
      "journal-title": "Clin Pharmacol Ther",
      "key": "157_CR48",
      "unstructured": "Lauschke VM, Ingelman-Sundberg M. How to consider rare genetic variants in personalized drug therapy. Clin Pharmacol Ther. 2018;19:20. \n                    https://doi.org/10.1002/cpt.976\n                    \n                  .",
      "volume": "19",
      "year": "2018"
    },
    {
      "DOI": "10.1016/j.tips.2015.10.006",
      "author": "VM Lauschke",
      "doi-asserted-by": "publisher",
      "first-page": "85",
      "issue": "2",
      "journal-title": "Trends Pharmacol Sci",
      "key": "157_CR49",
      "unstructured": "Lauschke VM, Ingelman-Sundberg M. Precision medicine and rare genetic variants. Trends Pharmacol Sci. 2016;37(2):85–6. \n                    https://doi.org/10.1016/j.tips.2015.10.006\n                    \n                  .",
      "volume": "37",
      "year": "2016"
    },
    {
      "DOI": "10.1038/nmeth.2811",
      "author": "M Spitzer",
      "doi-asserted-by": "publisher",
      "first-page": "121",
      "issue": "2",
      "journal-title": "Nat Methods",
      "key": "157_CR50",
      "unstructured": "Spitzer M, Wildenhain J, Rappsilber J, et al. BoxPlotR: a web tool for generation of box plots. Nat Methods. 2014;11(2):121–2. \n                    https://doi.org/10.1038/nmeth.2811\n                    \n                  .",
      "volume": "11",
      "year": "2014"
    }
  ],
  "reference-count": 50,
  "references-count": 50,
  "resource": {
    "primary": {
      "URL": "https://humgenomics.biomedcentral.com/articles/10.1186/s40246-018-0157-3"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genomics"
  ],
  "source": "Crossref",
  "title": [
    "Integrating rare genetic variants into pharmacogenetic drug response predictions"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "12"
}